Aurelio Maggio: Is It Time to Align Thalassemia Biology with Regulatory Science?
Aurelio Maggio, President of Foundation Franco and Piera Cutino, shared on LinkedIn:
”A Century After Cooley: Is It Time to Align Thalassemia Biology with Regulatory Science?
March 18–21, 2027 | Palermo, Italy
International GRADE-Based Consensus Conference
GARDEN Network – Global Hematological Rare Diseases Alliance
In 1925, Thomas Benton Cooley described what he called ‘Erythroblastic Anemia’, recognizing a profound disturbance in erythroid development.
More than a century later, thalassemia remains primarily classified as a globin gene disorder.
That molecular basis remains central.
However, translational evidence is expanding the framework.
Dysregulated hematopoietic stem cell (HSC) biology.
Persistent stress erythropoiesis. Metabolic hyperactivation. Epigenetic modulation.
These mechanisms appear to influence phenotypic heterogeneity, treatment responsiveness, disease-modifying potential, and long-term organ outcomes.
This is not a semantic issue. It is a regulatory one.
A stem cell–centered model could impact:
- Mechanism-based endpoint selection
- Biomarker qualification strategies
- Trial population stratification
- Surrogate endpoint validation
- Long-term follow-up architecture
In March 2027, we will convene the first international GRADE-based structured consensus to systematically assess this framework.
The goal is alignment — between biology, therapeutic innovation, and regulatory evaluation.
We welcome dialogue with regulatory authorities, HTA bodies, and industry partners interested in biologically coherent development strategies in rare hematologic diseases.
A century after its original description, reassessment may not be disruptive — it may be necessary.”
Stay updated with Hemostasis Today.
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management
-
Apr 12, 2026, 21:24Heghine Khachatryan: Diagnosing PNH in Resource-Limited Settings
-
Apr 12, 2026, 21:15Katariina Öörni: Role of Cholesterol Absorption Efficiency in Atherosclerosis
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes
-
Apr 12, 2026, 17:30Flora Peyvandi: ABB Milan Presentations During the ISTH 2026